CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives

Area of Science:

• Genetics and Molecular Biology
• Neuromuscular Disorders
• Gene Therapy

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic neuromuscular disease caused by dystrophin gene mutations.
• Current treatments for DMD are limited, with no cure available for this progressive and fatal disorder.
• DMD leads to muscle degeneration, respiratory failure, cardiac issues, and premature death.

Purpose of the Study:

• To provide an overview of CRISPR genome-editing systems for therapeutic applications.
• To summarize recent advancements in applying CRISPR technology to Duchenne muscular dystrophy.
• To discuss challenges and obstacles for the clinical translation of CRISPR-based gene therapy for DMD.

Main Methods:

• Review of CRISPR genome-editing technologies and their mechanisms.
• Analysis of recent studies demonstrating CRISPR efficacy in DMD models (cells, rodents, canines, piglets).
• Identification and discussion of hurdles for clinical implementation.

Main Results:

• CRISPR gene editing has shown success in correcting DMD-causing mutations in various preclinical models.
• Demonstrated restoration of dystrophin expression and function in affected tissues.
• Preclinical evidence supports the therapeutic potential of CRISPR for DMD.

Conclusions:

• CRISPR genome editing presents a novel therapeutic strategy for Duchenne muscular dystrophy by targeting genetic defects.
• Significant progress has been made in preclinical settings, validating the approach.
• Overcoming remaining challenges is crucial for the successful clinical translation of CRISPR-based DMD gene therapy.